Timber Pharmaceuticals Inc. (NYSE American: TMBR) Starts Presentation at The LD 500
Timber Pharmaceuticals Inc. (NYSE American: TMBR) is a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. The company's investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing and control) and safety profiles. The company is initially focused on developing non-systemic treatments for rare dermatologic diseases, including congenital ichthyosis (CI), facial angiofibromas (FAs) in tuberous sclerosis complex (TSC) and localized scleroderma. For more information, visit the company's website at www.timberpharma.com About The LD 500 The LD 500 is the most ambitious project in LD Micro's 14-year history of…







